Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs.

The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.

It also focuses on discovery and development of small molecule drug candidates. The company's platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment.

Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.